is tirzepatide a glp-1 Effects of tirzepatide, dual GIP and receptor agonist, on blood pressure, cardiac function, and sympathetic nervous system in stroke-prone spontaneously hypertensive rats Major physiological roles of GLP-1

Description

Sanofis GLP-1 Strategy Sanofis first try at a GLP-1 drug was in the obesity indication

Liraglutide has a half-life of 13h, and reaches brain tissue on crossing the blood brain barrier

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) demonstrate cardioprotective benefits that may extend beyond glycemic control, but their effects on key inflammatory and oxidative stress biomarkers compared to other glucose-lowering medications remain inconsistently reported across individual studies

In one of the initial long-term pivotal studies of patients with type 1 and insulin-requiring T2D where full-dose pramlintide was added to existing insulin regimens in double-blind fashion without titration, it was observed that the severe hypoglycemia event rate during the first 4 weeks of therapy was higher in the pramlintide group compared with the placebo group